Tiziana life sciences announces findings from intranasal anti-cd3 mab treatment in intracerebral hemorrhage at the annual american academy of neurology conference

New york, april 27, 2023 (globe newswire) -- tiziana life sciences ltd. (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced broad-based findings on the utility of nasal anti-cd3 mab in the treatment of intracerebral hemorrhage (ich). the data using a mouse model of collagenase-induced ich was presented at the annual american academy of neurology conference. the full presentation can be viewed at https://www.aan.com/msa/public/events/abstractdetails/52974 until may 14, 2023.
TLSA Ratings Summary
TLSA Quant Ranking